Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 43

1.

RE: Immune checkpoint profiles in luminal B breast cancer (Alliance).

Jézéquel P, Patsouris A, Guette C, Juin PP, Campone PM.

J Natl Cancer Inst. 2020 Mar 19. pii: djaa037. doi: 10.1093/jnci/djaa037. [Epub ahead of print] No abstract available.

PMID:
32191300
2.

Chemotherapy-induced senescence, an adaptive mechanism driving resistance and tumor heterogeneity.

Guillon J, Petit C, Toutain B, Guette C, Lelièvre E, Coqueret O.

Cell Cycle. 2019 Oct;18(19):2385-2397. doi: 10.1080/15384101.2019.1652047. Epub 2019 Aug 9.

PMID:
31397193
3.

OLFM4 Expression in Ductal Carcinoma In Situ and in Invasive Breast Cancer Cohorts by a SWATH-Based Proteomic Approach.

Valo I, Raro P, Boissard A, Maarouf A, Jézéquel P, Verriele V, Campone M, Coqueret O, Guette C.

Proteomics. 2019 Nov;19(21-22):e1800446. doi: 10.1002/pmic.201800446. Epub 2019 Aug 8.

PMID:
31318138
4.

Proteomics Approaches to Define Senescence Heterogeneity and Chemotherapy Response.

Petit C, Guillon J, Toutain B, Boissard A, Patsouris A, Lelièvre E, Guette C, Coqueret O.

Proteomics. 2019 Nov;19(21-22):e1800447. doi: 10.1002/pmic.201800447. Epub 2019 May 13.

PMID:
30968557
5.

iTRAQ-Based Quantitative Proteomic Analysis Strengthens Transcriptomic Subtyping of Triple-Negative Breast Cancer Tumors.

Jézéquel P, Guette C, Lasla H, Gouraud W, Boissard A, Guérin-Charbonnel C, Campone M.

Proteomics. 2019 Nov;19(21-22):e1800484. doi: 10.1002/pmic.201800484. Epub 2019 May 7.

PMID:
30951236
6.

Regulation of senescence escape by TSP1 and CD47 following chemotherapy treatment.

Guillon J, Petit C, Moreau M, Toutain B, Henry C, Roché H, Bonichon-Lamichhane N, Salmon JP, Lemonnier J, Campone M, Verrièle V, Lelièvre E, Guette C, Coqueret O.

Cell Death Dis. 2019 Feb 27;10(3):199. doi: 10.1038/s41419-019-1406-7.

7.

Characterization of increasing stages of invasiveness identifies stromal/cancer cell crosstalk in rat models of mesothelioma.

Nader JS, Abadie J, Deshayes S, Boissard A, Blandin S, Blanquart C, Boisgerault N, Coqueret O, Guette C, Grégoire M, Pouliquen DL.

Oncotarget. 2018 Mar 27;9(23):16311-16329. doi: 10.18632/oncotarget.24632. eCollection 2018 Mar 27.

8.

Regulation of senescence escape by the cdk4-EZH2-AP2M1 pathway in response to chemotherapy.

Le Duff M, Gouju J, Jonchère B, Guillon J, Toutain B, Boissard A, Henry C, Guette C, Lelièvre E, Coqueret O.

Cell Death Dis. 2018 Feb 7;9(2):199. doi: 10.1038/s41419-017-0209-y.

9.

BCL-XL directly modulates RAS signalling to favour cancer cell stemness.

Carné Trécesson S, Souazé F, Basseville A, Bernard AC, Pécot J, Lopez J, Bessou M, Sarosiek KA, Letai A, Barillé-Nion S, Valo I, Coqueret O, Guette C, Campone M, Gautier F, Juin PP.

Nat Commun. 2017 Oct 24;8(1):1123. doi: 10.1038/s41467-017-01079-1.

10.

[Contribution to tumor escape and chemotherapy response: A choice between senescence and apoptosis in heterogeneous tumors].

Jonchère B, Vétillard A, Toutain B, Guette C, Coqueret O.

Bull Cancer. 2016 Jan;103(1):73-86. doi: 10.1016/j.bulcan.2015.10.014. Epub 2016 Jan 4. Review. French.

PMID:
26762946
11.

Akt inhibition improves irinotecan treatment and prevents cell emergence by switching the senescence response to apoptosis.

Vétillard A, Jonchère B, Moreau M, Toutain B, Henry C, Fontanel S, Bernard AC, Campone M, Guette C, Coqueret O.

Oncotarget. 2015 Dec 22;6(41):43342-62. doi: 10.18632/oncotarget.6126.

12.

Prediction of Recurrence and Survival for Triple-Negative Breast Cancer (TNBC) by a Protein Signature in Tissue Samples.

Campone M, Valo I, Jézéquel P, Moreau M, Boissard A, Campion L, Loussouarn D, Verriele V, Coqueret O, Guette C.

Mol Cell Proteomics. 2015 Nov;14(11):2936-46. doi: 10.1074/mcp.M115.048967. Epub 2015 Jul 24.

13.

Gene-expression molecular subtyping of triple-negative breast cancer tumours: importance of immune response.

Jézéquel P, Loussouarn D, Guérin-Charbonnel C, Campion L, Vanier A, Gouraud W, Lasla H, Guette C, Valo I, Verrièle V, Campone M.

Breast Cancer Res. 2015 Mar 20;17:43. doi: 10.1186/s13058-015-0550-y.

14.

Irinotecan treatment and senescence failure promote the emergence of more transformed and invasive cells that depend on anti-apoptotic Mcl-1.

Jonchère B, Vétillard A, Toutain B, Lam D, Bernard AC, Henry C, De Carné Trécesson S, Gamelin E, Juin P, Guette C, Coqueret O.

Oncotarget. 2015 Jan 1;6(1):409-26.

15.

Olfactomedin-4 is a candidate biomarker of solid gastric, colorectal, pancreatic, head and neck, and prostate cancers.

Guette C, Valo I, Vétillard A, Coqueret O.

Proteomics Clin Appl. 2015 Feb;9(1-2):58-63. doi: 10.1002/prca.201400083. Epub 2014 Dec 28. Review.

PMID:
25400027
16.

Glioblastoma-associated stromal cells (GASCs) from histologically normal surgical margins have a myofibroblast phenotype and angiogenic properties.

Clavreul A, Guette C, Faguer R, Tétaud C, Boissard A, Lemaire L, Rousseau A, Avril T, Henry C, Coqueret O, Menei P.

J Pathol. 2014 May;233(1):74-88. doi: 10.1002/path.4332. Epub 2014 Feb 20.

PMID:
24481573
17.

Two-step OFFGEL approach for effective peptide separation compatible with iTRAQ labeling.

Rideau A, Besson D, Boissard A, Coqueret O, Guette C.

Proteomics. 2013 Nov;13(22):3261-6. doi: 10.1002/pmic.201300161. Epub 2013 Oct 20.

PMID:
24115339
18.

How should we define STAT3 as an oncogene and as a potential target for therapy?

Sellier H, Rébillard A, Guette C, Barré B, Coqueret O.

JAKSTAT. 2013 Jul 1;2(3):e24716. doi: 10.4161/jkst.24716. Epub 2013 Apr 16. Review.

19.

STAT3 as a new autophagy regulator.

Jonchère B, Bélanger A, Guette C, Barré B, Coqueret O.

JAKSTAT. 2013 Jul 1;2(3):e24353. doi: 10.4161/jkst.24353. Epub 2013 Aug 15.

20.

Circulating miRNAs as new activators of the JAK-STAT3 pathway.

Lam D, Barré B, Guette C, Coqueret O.

JAKSTAT. 2013 Jan 1;2(1):e22996. doi: 10.4161/jkst.22996.

21.

Comparison of spheroids formed by rat glioma stem cells and neural stem cells reveals differences in glucose metabolism and promising therapeutic applications.

Morfouace M, Lalier L, Bahut M, Bonnamain V, Naveilhan P, Guette C, Oliver L, Gueguen N, Reynier P, Vallette FM.

J Biol Chem. 2012 Sep 28;287(40):33664-74. Epub 2012 Jul 10.

22.

Identification of potential prognostic biomarkers for node-negative breast tumours by proteomic analysis: a multicentric 2004 national PHRC study.

Descotes F, Jézéquel P, Spyratos F, Campion L, Grenot C, Lerebours F, Campone M, Guérin-Charbonnel C, Lanoë D, Adams M, André J, Carlioz A, Martin PM, Chassevent A, Jourdan ML, Guette C, Zanella-Cleon I, Ricolleau G.

Int J Oncol. 2012 Jul;41(1):92-104. doi: 10.3892/ijo.2012.1456. Epub 2012 Apr 30.

PMID:
22552268
23.

Intestinal cell targeting of a stable recombinant Cu-Zn SOD from Cucumis melo fused to a gliadin peptide.

Intes L, Bahut M, Nicole P, Couvineau A, Guette C, Calenda A.

J Biotechnol. 2012 May 31;159(1-2):99-107. doi: 10.1016/j.jbiotec.2012.02.019. Epub 2012 Mar 7.

PMID:
22426094
24.

A quantitative proteomic approach of the different stages of colorectal cancer establishes OLFM4 as a new nonmetastatic tumor marker.

Besson D, Pavageau AH, Valo I, Bourreau A, Bélanger A, Eymerit-Morin C, Moulière A, Chassevent A, Boisdron-Celle M, Morel A, Solassol J, Campone M, Gamelin E, Barré B, Coqueret O, Guette C.

Mol Cell Proteomics. 2011 Dec;10(12):M111.009712. doi: 10.1074/mcp.M111.009712. Epub 2011 Oct 10.

25.

Differential protein modulation in midguts of Aedes aegypti infected with chikungunya and dengue 2 viruses.

Tchankouo-Nguetcheu S, Khun H, Pincet L, Roux P, Bahut M, Huerre M, Guette C, Choumet V.

PLoS One. 2010 Oct 5;5(10). pii: e13149. doi: 10.1371/journal.pone.0013149.

26.

A proteomic approach for plasma biomarker discovery with iTRAQ labelling and OFFGEL fractionation.

Ernoult E, Bourreau A, Gamelin E, Guette C.

J Biomed Biotechnol. 2010;2010:927917. doi: 10.1155/2010/927917. Epub 2009 Nov 1.

27.

Affinity capture using chimeric membrane proteins bound to magnetic beads for rapid ligand screening by matrix-assisted laser desorption/ionization time-of-flight mass spectrometry.

Legros C, Guette C, Martin-Eauclaire MF, Goyffon M, Tortajada J.

Rapid Commun Mass Spectrom. 2009 Mar;23(6):745-55. doi: 10.1002/rcm.3939.

PMID:
19204930
28.

Improved proteome coverage by using iTRAQ labelling and peptide OFFGEL fractionation.

Ernoult E, Gamelin E, Guette C.

Proteome Sci. 2008 Oct 13;6:27. doi: 10.1186/1477-5956-6-27.

29.

Characteristics of human intestinal Escherichia coli with changing environments.

Skurnik D, Bonnet D, Bernède-Bauduin C, Michel R, Guette C, Becker JM, Balaire C, Chau F, Mohler J, Jarlier V, Boutin JP, Moreau B, Guillemot D, Denamur E, Andremont A, Ruimy R.

Environ Microbiol. 2008 Aug;10(8):2132-7. doi: 10.1111/j.1462-2920.2008.01636.x. Epub 2008 May 4.

PMID:
18459976
30.

Outbreak of malaria among policemen in French Guiana.

Michel R, Ollivier L, Meynard JB, Guette C, Migliani R, Boutin JP.

Mil Med. 2007 Sep;172(9):977-81.

PMID:
17937363
31.

Wnt signaling in hydroid development: ectopic heads and giant buds induced by GSK-3beta inhibitors.

Müller W, Frank U, Teo R, Mokady O, Guette C, Plickert G.

Int J Dev Biol. 2007;51(3):211-20.

32.

The antileishmanial activity assessment of unusual flavonoids from Kalanchoe pinnata.

Muzitano MF, Tinoco LW, Guette C, Kaiser CR, Rossi-Bergmann B, Costa SS.

Phytochemistry. 2006 Sep;67(18):2071-7. Epub 2006 Aug 23.

PMID:
16930642
33.

Kalanchosine dimalate, an anti-inflammatory salt from Kalanchoe brasiliensis.

Costa SS, de Souza Mde L, Ibrahim T, de Melo GO, de Almeida AP, Guette C, Férézou JP, Koatz VL.

J Nat Prod. 2006 May;69(5):815-8.

PMID:
16724848
34.

Peptide profiling by matrix-assisted laser desorption/ionisation time-of-flight mass spectrometry of the Lasiodora parahybana tarantula venom gland.

Guette C, Legros C, Tournois G, Goyffon M, Célérier ML.

Toxicon. 2006 May;47(6):640-9. Epub 2006 Apr 25.

PMID:
16635501
35.

Solution structure of PcFK1, a spider peptide active against Plasmodium falciparum.

Pimentel C, Choi SJ, Chagot B, Guette C, Camadro JM, Darbon H.

Protein Sci. 2006 Mar;15(3):628-34. Epub 2006 Feb 1.

36.

Quercitrin: an antileishmanial flavonoid glycoside from Kalanchoe pinnata.

Muzitano MF, Cruz EA, de Almeida AP, Da Silva SA, Kaiser CR, Guette C, Rossi-Bergmann B, Costa SS.

Planta Med. 2006 Jan;72(1):81-3.

PMID:
16450304
37.

[Dangerous scorpions from Niger].

Goyffon M, Guette C.

Bull Soc Pathol Exot. 2005 Nov;98(4):293-5. French.

PMID:
16402579
38.

First report in a river in France of the benthic cyanobacterium Phormidium favosum producing anatoxin-a associated with dog neurotoxicosis.

Gugger M, Lenoir S, Berger C, Ledreux A, Druart JC, Humbert JF, Guette C, Bernard C.

Toxicon. 2005 Jun 1;45(7):919-28. Epub 2005 Apr 13.

PMID:
15904687
39.

Isolation and characterization of Psalmopeotoxin I and II: two novel antimalarial peptides from the venom of the tarantula Psalmopoeus cambridgei.

Choi SJ, Parent R, Guillaume C, Deregnaucourt C, Delarbre C, Ojcius DM, Montagne JJ, Célérier ML, Phelipot A, Amiche M, Molgo J, Camadro JM, Guette C.

FEBS Lett. 2004 Aug 13;572(1-3):109-17.

40.

Modulation of Kv4.2 channels by a peptide isolated from the venom of the giant bird-eating tarantula Theraphosa leblondi.

Ebbinghaus J, Legros C, Nolting A, Guette C, Celerier ML, Pongs O, Bähring R.

Toxicon. 2004 Jun 15;43(8):923-32.

PMID:
15208026
42.

Supplemental Content

Loading ...
Support Center